Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4048 - Chemoradiotherapy versus radiotherapy in the treatment of salivary glands and nasal tumors: the GORTEC 2016-02 study

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Surgical Oncology;  Radiation Oncology;  Head and Neck Cancers

Presenters

Francois Regis Ferrand

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

F.R. Ferrand1, J. Thariat2, N. Vulquin3, V. Calugaru4, O. Malard5, C. Murariu6, F. Janot7, F. Louat8, C. Michel9, J. Bourhis10

Author affiliations

  • 1 Medical Oncology, Bégin Military Teaching Hospital, 94160 - Saint-Mandé/FR
  • 2 Radiotherapy, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 3 Radiotherapy, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 4 Centre De Protonthérapie D’orsay, Institut Curie, Paris/FR
  • 5 Head And Neck Surgery, CHU Nantes, Nantes/FR
  • 6 Radiotherapy, Institut Jean Godinot, Reims/FR
  • 7 Head And Neck Surgery, Gustave Roussy, Villejuif/FR
  • 8 Clinical Research, GORTEC, Tours/FR
  • 9 Clinical Research, GORTEC, Nice/FR
  • 10 Radiotherapy, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
More

Resources

Abstract 4048

Background

Carcinomas of sinuses and salivary glands are rare and heterogeneous in terms of anatomical sites and histology subtypes. For these reasons and because of the absence of prospective study results, their treatment is still largely extrapolated from data of frequent carcinomas of the upper digestive tract. Treatment is based on surgery and radiotherapy (proof level grade C). Despite the advances, the 5-year overall survival does not exceed 65%, mainly due to locoregional recurrence. In this context, chemotherapy administered concomitantly with radiotherapy could increase the efficacy of locoregional treatment by radiosensitization, regardless of the histology.

Trial design

The GORTEC launched a multicenter, phase III randomized, open-label, study evaluating in case of high-risk of locoregional relapse, the impact of the addition after surgery of cisplatin 100 mg/m2 (every 3 weeks; 3 cycles) to radiotherapy. The population is defined as patients with radioresistant histologies (e.g. cystic adenoids carcinomas) or patients with unfavorable histoprognostic critera (e.g. incomplete resection, T4 tumor, malignant lymph node(s) with capsular rupture, presence of emboli, …). The primary endpoint is the progression free survival. Secondary outcomes are: overall survival, quality of life, time to progression (locoregional and distant) and toxicities. Two hundred and sixty patients will be enrolled in 5 years. Eligible patients are adults, with a performance status ≤ 2 and an adequate hematological and renal function for cisplatin treatment. Recruitment is ongoing in France. The study comprises a quality insurance program in radiotherapy and surgery. Coordinating investigators are Drs Ferrand and Thariat.

Clinical trial identification

NCT02998385.

Legal entity responsible for the study

GORTEC (Groupe Oncologie Radiothérapie Tête et Cou)

Funding

GORTEC

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.